Abeona Therapeutics Inc. issued a press release on March 9, 2026, providing a business update on the building momentum in the ZEVASKYN commercial launch, including first patient treatment in December 2025, resumed manufacturing in late January 2026, and coverage by all major commercial payers and Medicaid programs.
Key takeaways
ZEVASKYN commercial launch commenced in Q4 2025 with first patient treatment completed in December 2025
Multiple biopsies collected and one patient completed treatment since manufacturing resumed in late January 2026
Policies covering ZEVASKYN published by United Healthcare, Cigna, Aetna, Anthem, and most Blue Cross Blue Shield plans (80% of commercial insurance lives)
ZEVASKYN secured coverage across all Medicaid programs
CMS established permanent HCPCS J-code J3389 for ZEVASKYN effective January 1, 2026
Additional biopsies scheduled for remainder of Q1 2026